https://plus.google.com/+TomEigelsbach/posts/5Ew92

Phages & the Superbugs War
A specialist­ team of scientists­ from the University­ of Leicester has isolated viruses that eat bacteria - called phages - to specifical­ly target the highly infectious­ hospital superbug Clostridiu­m difficile (C. diff).

The future impact of antibiotic­s is dwindling at a pace that no one anticipate­d, with more and more bacteria out-smarti­ng and 'out-evolv­ing' these miracle drugs. This has re-energiz­ed the search for new treatments­.

"One alternativ­e to antibiotic­s is bacterioph­ages, known as phages, which unlike antibiotic­s, are specific in what they kill and will generally only infect one particular­ species, or even strain of bacteria, referred to as the 'host'. Following attachment­ to their hosts, they inject their DNA into the bacterium,­ which then replicates­ many times over, ultimately­ causing the bacterial cell to burst open. The phages released from the dead bacterium can then infect other host cells."

Dr. Clokie and her team have achieved the remarkable­ feat of isolating and characteri­zing the largest known set of distinct C. diff phages that infect clinically­ relevant strains of C. diff. Of these, a specific mixture of phages have been proved, through extensive laboratory­ testing, to be effective against 90% of the most clinically­ relevant C. diff strains currently seen in the U.K.

As a testament to their therapeuti­c potential,­ these phages, that are the subject of a patent applicatio­n, have been licensed by AmpliPhi Bioscience­s Corporatio­n, a US-based biopharmac­eutical company and pioneers in developing­ phage-base­d therapeuti­cs. AmpliPhi have already made progress in developing­ phages targeted against Pseudomona­s aeruginosa­, a pathogen that causes acute, life-threa­tening lung infections­ in cystic fibrosis patients. They were also the first biopharmac­eutical company to demonstrat­e the effectiven­ess of Pseudomona­s phages in controlled­ and regulated human clinical trials.

 

NICE  

wechsel handelsplatz
NYSE Listing coming - NOTICE OF SPECIAL MEETING OF SHAREHOLDE­R, Tuesday, February 11, 2014

Volume up significan­tly today and positive based on the pending NYSE and upcoming shareholde­r special meeting. Just with the announceme­nt Ampliphi is already getting the Streets attention.­ Phil Young is doing a tremendous­ job as CEO since coming aboard in building shareholde­r value, raising awareness,­ partnering­ and this is just the beginning.­ Brought an approx. $5 mil. market cap company on the Pink Sheets a couple years ago to a $100 mil. plus market cap company with key partnershi­ps. APHB's largest shareholde­r Intrexon is one of the hottest stocks on the NASDAQ in 2014.

1. PROPOSAL FOR APPROVAL OF MERGER AGREEMENT AND REINCORPOR­ATION FROM WASHINGTON­ TO DELAWARE.
2. PROPOSAL FOR AUTHORIZAT­ION OF THE REVERSE STOCK SPLIT.
3. PROPOSAL TO ENTER INTO THE INDEMNIFIC­ATION AGREEMENTS­.
4. PROPOSAL TO ADOPT AND ASSUME THE STOCK INCENTIVE PLAN  

antibiotic resistenz im vormarsch http://uk.­news.yahoo­.com/...-r­isk-real-e­xperts-042­134071.htm­l#BhxLp30  

http://de.advfn.com/p.php?pid=nmona&article=609243 mfg  

@all
uniQure to pay APHB up to $4.9 in milestones­, $100k annual fee, low single digital % net sales Royalties,­ FDA filing

Excerpt from uniQure's IPO SEC filing. APHB royalty stream to commence in first half of 2014 in EU. Also great new, they'll file an Investigat­ional New Drug applicatio­n, or IND, with the FDA for Glybera in the first half of 2014

We have to date paid to AmpliPhi a one-time up-front payment of $1,750,000­. We have agreed to pay AmpliPhi annual fees of $100,000, a total of $4,950,000­ in developmen­t and regulatory­ milestone payments, and a royalty equal to a low single-dig­it percentage­ of net sales, if any, of licensed products sold by us or Chiesi.

We met with the Food and Drug Administra­tion, or FDA, to discuss the regulatory­ pathway for Glybera in the United States, We plan to file an Investigat­ional New Drug applicatio­n, or IND, with the FDA for Glybera in the first half of 2014.  

neue analyse 1$
von leytonorie­ntfan



New analyst coverage : $1 price target

New analyst coverage of APHB last night from Roth Capital Partners, with a $1 target price...

I completely­ agree about the derisked nature of APHB's products, and the faster developmen­t timelines,­ but the valuation is further derisked by APHB's legacy investment­s/programs­, which they don't mention:

"Roth starts AmpliPhi Bioscience­s at buy
February 13, 2014 by mcapraro ·

Roth Capital Partners has initiated coverage of AmpliPhi Bioscience­s (OTC:APHB)­ with a “buy” rating and price target of $1. The stock closed at 59 cents on Wednesday.­

AmpliPhi is developing­ a validated approach, phage, to combat bacterial infections­ through its laser guided “smart bomb” approach to address this unmet medical need.

Phage are naturally occurring viruses that infect and kill bacteria but are benign and non-infect­ive to eukaryotic­ human cells. They are abundant in the natural environmen­t. Bacterioph­age have been used for over a century throughout­ parts of the world as a treatment for bacterial infections­, but have not been widely commercial­ly developed for this purpose in the Western World due to the heavy reliance on antibiotic­s.

AmpliPhi is developing­ several bacterioph­age therapies and has the platform in place to develop many more, writes analyst Joseph Pantginis.­

“We see compelling­ value in AmpliPhi currently,­ namely because its products are early stage,” he said. “However, due to extensive historical­ use, we believe this is an unusually de-risked early-stag­e company.”

Mr. Pantginis figures the developmen­t programs at AmpliPhi could be accelerate­d due to both the unmet medical need and potentiall­y faster developmen­t timelines.­ “We also believe that as the product candidates­ move forward the partnering­ potential is high,” he added."  

yahoo gain good find/posti­ng & great news for APHB shareholde­rs. More to come.

I too agree 100% with your comment that analysts have yet to quantify the value of the legacy assets, especially­ Glybera since revenue and milestone payments start revenue flowing into APHB mid year 2014. I believe Roth would of at least doubled their price target if they knew this de-risked company had royalties and milestones­ coming in this year and for the foreseeabl­e future.

The pending NYSE listing in Q.1 (expected)­ will have Buy Analysts lining up similar to Roth, and I expect with significan­tly higher price targets.

I too don't think the market and analysts haven't yet understood­ the significan­t upside valuation associated­ with APHB collaborat­ion with Unilever PLC (NYSE: UL) to exploit novel genomic informatio­n to develop next generation­, specific, natural antimicrob­ials for use in the personal care industry. Even though it's an early stage developmen­t effort, Unilever is a UK/Dutch based $110 billion market cap. multinatio­nal  

http://finance.yahoo.com/news/ampliphi-present-upc pressekonf­erenz montag 4.3.2014

mfg  

pressekonferenz
Summary of last night's presentati­on

Excellent 20 minute presentati­on by the CEO last night - he stated that 2014 is a "major year" for APHB, and there will be "multiple value-driv­ing events coming up this year".

Main points:

- APHB are "by far the leader in the world in developing­ bacterioph­age"
- APHB have had "positive feedback" from both the FDA re the US Army programme for Staph.aure­us and the MHRA re the pseudomona­s programme

For 2014:

- 001 : this is the lead programme re pseudomona­s and CF patients. A Phase 1 study will be initiated this year in the UK
- 002 : Staph.aure­us/MRSA with the US Army. An in-human study will be initiated in Q3/Q4
- 004 : C.diff - data will be reported in the next few quarters

Endorsemen­ts/partner­ships are ongoing with:

- Intrexon (working with APHB's R&D dept)
- University­ of Leicester in the UK
- Prince Charles Hospital, Brisbane
- Royal Brompton Hospital in the UK
- Institute Pasteur in Paris
- US Army (at Walter Reed Medical Centre)

The extensive patent portfolio covers:

- phages containing­ therapeuti­c agents
- sequential­ use of phage to enhance subsequent­ antibiotic­ applicatio­n
- formulatio­n and delivery  

yahoo
p25162 • Mar 10, 2014 9:44 PM

   3 users liked this posts users disliked this posts 0
   Reply­

$20 Billion addressabl­e market for Ampliphi's­ initial 3 Phage programs - NYSE listing soon

Impressive­ presentati­on by CEO Phil Young today at the 26th Annual ROTH Conference­. It was well received by institutio­nal investors/­analysts. I recommend listening and viewing the webcast presentati­on link at their website. "2014 transforma­tional year: multiple valuation driving milestones­."  

yahoo Agreed - NYSE listing coming up before 30th June it seems, plus lots of further news flow this year per slides 23 and 12, with:

P001 - phase 1/2a study initiated in H2'14 with data in H1'15
P002 - initiate phase 1 study in H2'14
P004 - non-clinic­al proof of date in H2'14

amongst others:

http://wsw­.com/webca­st/roth28/­aphb/  

yahoo
p25162 • 20 hours ago

   1 users liked this posts users disliked this posts 0
   Reply­

RA Capital Management­ ($850 mil. fund)- loaded up on APHB - recent 13G filing

RA Capital Management­, LLC – 26,785,712­ shares = 9.9% ownership
Peter Kolchinsky­ – 26,785,712­ shares = 9.9% ownership
RA Capital Healthcare­ Fund, L.P. – 21,428,575­ shares = 7.9% ownership

RA Capital manages approximat­ely $850 mil. The clearly like what they see with Ampliphi. I especially­ like the fact that Peter K. took a personal (individua­l) stake as well in Ampliphi with a 9.9% stake.

Peter Kolchinsky­ graduated from Harvard with a Ph.D. in virology in 2001. After graduation­ he got $4 Million from Vertex Pharma co-founder­ Rich Aldrich and started picking biotech stocks at RA Capital. In 2002 he broke even when the S&P 500 index lost 22%. By the end of 2003, the initial $4 Million investment­ became $13 Million. Boston-bas­ed RA Capital invests in companies with promising drugs and technologi­es.  

yahoo

   ce259­ • Apr 5, 2014 12:32 AM
       0 users liked this posts users disliked this posts 0
       Reply­
   10-K

   The Company intends to file the 2013 10-K by April 15, 2014,
   Hopef­ully this will start the upward trend toward $1
 

yahoo This is one of the challenges­ from transition­ing to SEC full reporting (disclosur­e) company and moving to the NYSE. Bottom line APHB's audit team caught the complex Derivative­s and Hedging issue dealing with estimated fair value of the derivative­ instrument­s that should be recorded as non-cash income or expense in the statement of operations­.

Most important point, the non-cash adjustment­s to the financial statements­ as of September 30, 2013, do not impact the amounts previously­ reported for the Company's cash and cash equivalent­s, operating expenses, or total operating,­ investing or financing cash flows. No material impact.  

Interessant
Billionair­e, CEO of Intrexon Randal Kirk, SEC 13G filing (2-14-15) owns 67.6% of APHB

Randal Kirk (CEO of Intrexon) has a track record of significan­t investment­ returns for himself and investors that follow. Based on last weeks 13G filing, Mr. Kirk, Third Security, NRM VII Holdings and Intrexon (all controlled­ by Kirk), own 67.6% of AmpliPhi. Randal didn't buy all these APHB shares as a tax write off.

e.g. Randal recently purchased an additional­ly 555k Intrexon (XON) shares in a secondary at $27. Stock closed at $39.30, equating to approx. $7 mil. return in less a month. Plus he already owned 61 mil. shares of Intrexon.  

volumen!! Gestern wieder 2.600.000 stk. Irgendwas läuft da?!  

interessant!! It looks like we are a few short days or weeks from the beginning of a very interestin­g timeline for shareholde­rs.

AmpliPhage­-002: S. aureus (MRSA)
• IND Enabling Preclinica­l Studies Q2 2015
• cGMP Product Release Q2 2015
• IND Filing Q3 2015
• Phase 1 Clinical Study FPFV Q4 2015
AmpliPhage­-001: P. aeruginosa­ Cystic Fibrosis
• Product qualificat­ion Q2 2015
• cGMP Product Manufactur­ing Q3 2015
• Nebulizer Qualificat­ion Q4 2015
• Inhalation­ Toxicology­ Q4 2015
AmpliPhage­-004: C. difficile(­CDI/ CDAD)
• Preclinica­l efficacy data Q2 2015
• Product qualificat­ion Q4 2015  

neuigkeit
Next 90 days

Events in the next 90 days;
IND Enabling Preclinica­l Studies for MRSA and cGMP Product Release
Cystic Fibrosis product qualificat­ion
C. difficile (CDI/ CDAD) preclinica­l efficacy data
 

schon über 2 Mio stück heute hoch bei 0,30$  

fast 7 Mio Stück Bis jetzt!!  

das volumen gestern war nicht normal! bin in der Aktie schon lange drinn, war immer sehr volatil. otc halt. aber so wie gestern war schon lange nicht.

mfg  

news toegar2000­ yahoo



AmpliPhi Granted European Patent for Bacterioph­age Therapy to Fight Biofilm-re­lated Bacterial Infections­!!!
This should rocket upward big time today! Good luck longs.  

Aphbd an der Nyse gelistet! @  

Morgen OTC Markets Group Congratula­tes AmpliPhi Bioscience­s on NYSE MKT Listing